Exarafenib, a pan-RAF inhibitor being investigated as a monotherapy in BRAF and NRAS-driven solid tumors by Kinnate Biopharma, was well-tolerated and demonstrated early signs of activity with durable responses in various patient populations, including those with BRAF Class II and NRAS-mutant melanoma, according to early Phase I trial results.
2023
DecisionDx-Melanoma 31-Gene Expression Profile Test Stratifies Patients With Cutaneous Melanoma
The DecisionDx-Melanoma 31-gene expression profile test displayed the capability to stratify patients with cutaneous melanoma by risk of death from the disease and receival of the 31-GEP test may result in a survival benefit compared with untested patients.
Episode 1: The Role of Adjuvant and Neoadjuvant Therapy in Melanoma Melanoma Podast: by Sapna P. Patel; Matteo Carlino, PhD
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider.
Luke Breaks Down Key Clinical Trial Updates From the 2023 ASCO Annual Meeting
Jason Luke, MD, FACP, discusses key takeaways from the KEYNOTE-716 and KEYNOTE-942 trials and other key updates from across the melanoma landscape presented at the 2023 ASCO Annual Meeting.